HR
MTNB icon

Howe & Rusling’s Matinas BioPharma MTNB Stock Holding History

Howe & Rusling’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed – – 768
2022
Q3 		$0 Hold
10
– – ﹤0.01% 1143
2022
Q2 		$0 Hold
10
– – ﹤0.01% 1129
2022
Q1 		$0 Hold
10
– – ﹤0.01% 1053
2021
Q4 		$1K Hold
10
– – ﹤0.01% 942
2021
Q3 		$1K Sell
10
-10
-50% -$431 ﹤0.01% 930
2021
Q2 		$1K Hold
20
– – ﹤0.01% 890
2021
Q1 		$1K Buy
+20
New +$1.34K ﹤0.01% 897

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Howe & Rusling's MTNB Position: Q4 2022 in Review

Howe & Rusling sold out of Matinas BioPharma (MTNB) in Q4 2022, closing a stake of 10 shares.

Howe & Rusling first reported a position in MTNB in Q1 2021 and held it in 7 quarters. The position peaked at $1K in Q4 2021. 57 funds tracked by Wall St. Rank hold MTNB as of Q4 2022.

  • Howe & Rusling reported no remaining Matinas BioPharma position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 10 Matinas BioPharma shares in Q4 2022.
  • Howe & Rusling first reported a position in Matinas BioPharma in Q1 2021 and held it in 7 quarters.
  • Howe & Rusling's Matinas BioPharma position peaked at $1K in Q4 2021.
  • 57 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.